APC Anti-human CD5 Antibody

Our laboratory investigates different ways to improve immune responses against HIV, including enhancement of the capacity of effector cells, such as NK cells, to kill HIV-infected cell. We are currently investigating the capacity of an engineered antibody to trigger NK-cell mediated ADCC activity in in vitro assays against an HIV-infected cell line, ACH2, which expresses high levels of human CD5. We perform FACS-based killing assays, where we use human CD5 as a marker to distinguish the target cells.